Standard BioTools Inc.: sells Microfluidics business to ARCHIMED

What happened

• On Oct 5, 2026, Standard BioTools Inc., a Delaware corporation, issued a press release announcing that it has entered into a definitive agreement with respect to the sale of its Microfluidics business to ARCHIMED, a leading investment firm focused exclusively on healthcare industries.
• The filing says the transaction is expected to close in approximately 30 days, subject to customary closing conditions. The press release is furnished as Exhibit 99.1 and is incorporated by reference.

Key details

• Date of announcement: Oct 5, 2026.
• Buyer: ARCHIMED.
• Expected close: approximately 30 days, subject to customary closing conditions.
• Press release filed as Exhibit 99.1 to the Form 8-K.

Why it may matter

• Item 7.01 (Regulation FD Disclosure) was reported, covering the press release announcing the agreement to sell the Microfluidics business.
• Item 9.01 was reported to furnish the press release as an exhibit to the Form 8-K.
• The filing does not show why the insider traded or why the company acted.